



February 28, 2023

Notice Regarding Refunds to 340B Covered Entities

Dermavant Sciences Inc., (“Dermavant”) has asked the Office of Pharmacy Affairs to post this notice on their public website to ensure transparency.

Dermavant began selling VTAMA[®] (tapinarof) cream, 1% (NDC 11: 81672-5051-01) in May 2022. Dermavant has discovered that some 340B Covered Entities may have purchased VTAMA cream at the Wholesaler Acquisition Price (WAC) instead of the 340B Ceiling Price for the quarters 2Q2022 through Q12023.

Known affected Covered Entities were contacted by Dermavant by February 28, 2023. If you purchased VTAMA cream at a price higher than the 340B Ceiling Price and you haven’t heard from Dermavant, please contact Dermavant via email at: dermavantsptr@dermavant.com with a subject line of “340B Reimbursement” and your entity’s 340B ID.

In addition, please include Invoice Date, Wholesaler Purchased from, Quantity Purchased, Invoiced Amount, and Purchase Invoice Number in the body of your email so that we can research your inquiry and reimburse as necessary. Refunds will be issued as a credit to a Covered Entity’s wholesaler pharmacy account when one can be identified, or a check will be issued to the Covered Entity when a credit cannot be processed.